title: Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation.
abstract: This retrospective study was designed to evaluate the effectiveness of subcutaneous heparin therapy for the treatment of protein-losing enteropathy (PLE) associated with single-ventricle palliation and to evaluate the side effects of long-term heparin use. PLE affects 4% to 13% of Fontan operative survivors. Five-year survival after onset of PLE is only 46% to 59%. We studied a cohort of patients with single-ventricle palliation who developed PLE and were treated with subcutaneous heparin. Seventeen patients were included in the study. Symptoms of PLE appeared on average 43 months after surgical palliation. At diagnosis of PLE, mean albumin level was 2.0 +/- 0.4 g/dl. At cardiac catheterization, mean systemic venous pressure was 11.6 mm Hg. Subjective symptomatic improvement on heparin therapy occurred in 13 patients (76%). Three patients (18%) went into clinical remission. Compared with the period before initiation of heparin, there was no significant difference in the number of hospital admissions (p = 0.99) or albumin infusions (p = 0.88) during the first year of heparin therapy. Five patients had x-rays of their thoracolumbar spine, and 9 patients had bone mineral analyses; all scans were grossly abnormal. In conclusion, subcutaneous heparin therapy leads to subjective improvement of PLE symptoms in most patients; however, it does not change the need for frequent albumin infusions and does not increase the rate of remission above that for standard medical therapy.
authors.affiliation: Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Ryerson
authors.forename: Caren
authors.initials: C
authors.lastname: Goldberg
authors.forename: Amnon
authors.initials: A
authors.lastname: Rosenthal
authors.forename: Aimee
authors.initials: A
authors.lastname: Armstrong
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D015331:Cohort Studies; D005260:Female; D006352:Heart Ventricles / Q000473:pathology*; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008499:Medical Records; D008824:Michigan / Q000453:epidemiology; D011504:Protein-Losing Enteropathies / Q000097:blood / Q000188:drug therapy* / Q000401:mortality*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000925:Anticoagulants; D006493:Heparin